Table 1.
Baseline characteristics of men with csPCa outside of the MRI lesion detected on systematic biopsy.
| Baseline characteristic | Total | No csPCa | csPCa detected outside of MRI lesion | p value |
|---|---|---|---|---|
| Patients, n (%) | 398 | 315 (79) | 83 (21) | |
| Race, n (%) | ||||
| Chinese | 347 (87) | 277 (88) | 70 (84) | |
| Non-Chinese | 51 (13) | 38 (12) | 13 (16) | 0.383 |
| Mean Age, years (±SD) | 65.7 (±7.8) | 64.9 (±7.7) | 68.6 (±7.4) | <0.001 |
| Prior negative biopsy, n (%) | 133 (33) | 122 (39) | 11 (13) | <0.001 |
| Mean prebiopsy PSA, ng/mL (±SD) (n = 393) | 10.1 (±8.4) | 9.6 (±7.2) | 12.2 (±10.7) | 0.045 |
| Mean MRI-US fusion prostate volume, mL (±SD) | 43.5 (±18.6) | 45.3 (±18.2) | 36.7 (±18.5) | <0.001 |
| Mean PSAD | 0.27 (±0.25) | 0.24 (±0.22) | 0.38 (±0.33) | <0.001 |
| Median number of MRI lesions (IQR) | 2 (1–2) | 2 (1–2) | 2 (1–3) | 0.093 |
| PI-RADS score | ||||
| 3 (%) | 69 (18) | 68 (22) | 1 (1) | |
| 4 (%) | 240 (60) | 191 (61) | 49 (59) | |
| 5 (%) | 89 (22) | 56 (17) | 33 (40) | <0.001 |
| Median number of cores, n (IQR) | ||||
| Total | 33 (28–39) | 33 (28–39) | 32 (26–36) | 0.038 |
| Systematic | 23 (19–29) | 24 (20–29) | 21 (18–26) | 0.004 |
| Targeted | 9 (6–12) | 9 (6–12) | 9 (7–12) | 0.105 |
| Median number of overlap cores, n (IQR) | 5 (4–7) | 5 (4–7) | 5 (4–7) | 0.408 |
GG Grade Group, PSAD prostate specific antigen density, PI-RADS Prostate Imaging—Reporting and Data System.